Serpinb10 (SPB10_HUMAN): A Promising Drug Target and Biomarker

Target Name: SERPINB10

NCBI ID: G5273

SERPINB10

Serpinb10 (SPB10_HUMAN): A Promising Drug Target and Biomarker

Introduction

Serpins are a family of proteins that regulate the interactions between various bioactive molecules, including fibrin and thrombin. These proteins play a crucial role in the regulation of blood clotting and have been implicated in the development of various cardiovascular diseases. The serpin family consists of ten subunits, including SERPINB10 (SPB10_HUMAN), which is a key member of this family.

SERPINB10 (SPB10_HUMAN) is a 10-kDa protein that is expressed in various tissues and cells, including platelets, endothelial cells, and liver cells. It is a potent inhibitor of thrombin and has been shown to have anti-inflammatory properties. The results of In vitro and in vivo experiments have suggested that SPB10 may be a promising drug target for the prevention and treatment of thromboembolic diseases.

Drug Target Potential

SPB10 has been identified as a potential drug target due to its unique structure and its ability to interact with various bioactive molecules. Its inhibitory activity against thrombin has been shown to be dose-dependent and can be reversible by the addition of exogenous thrombin. Additionally, SPB10 has been shown to interact with other proteins involved in the regulation of blood clotting, including the proteinase-activated receptor (PAR-1) and the proteinase-activated receptor (PAR-2).

The potential drug target for SPB10 is the thrombin, which is a protein that is involved in the regulation of blood clotting. Thrombin is a potent enzyme that can catalyze the production of thrombin-activated plasmin (a protein that can break down blood clots ), which is essential for the formation of a stable blood clot. The inhibition of thrombin by SPB10 has been shown to prevent the formation of blood clots in various experimental models, including in vitro and in vivo systems.

Biomarker Potential

SPB10 has also been identified as a potential biomarker for the diagnosis and monitoring of thromboembolic diseases. The formation of blood clots is a key event in the development of thromboembolic diseases, including stroke, heart attack, and deep vein thrombosis (DVT). The inhibition of SPB10 by drugs that are currently being developed as thromboembolic disease treatments has the potential to increase the effectiveness of these treatments.

SPB10 has been shown to be expressed in various tissues and cells, including platelets, endothelial cells, and liver cells. It has also been shown to be involved in the regulation of thrombin activation and to interact with other proteins involved in the regulation of blood clotting . These properties make SPB10 an attractive biomarker for the diagnosis and monitoring of thromboembolic diseases.

Conclusion

In conclusion, SERPINB10 (SPB10_HUMAN) is a promising drug target and biomarker for the prevention and treatment of thromboembolic diseases. Its inhibitory activity against thrombin and its ability to interact with other proteins involved in the regulation of blood clotting make it an attractive target for drug development. Further studies are needed to fully understand the potential of SPB10 as a drug target and biomarker for thromboembolic diseases.

Protein Name: Serpin Family B Member 10

Functions: Protease inhibitor that may play a role in the regulation of protease activities during hematopoiesis and apoptosis induced by TNF. May regulate protease activities in the cytoplasm and in the nucleus

The "SERPINB10 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SERPINB10 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets